arrow
D

David J. Kuter

Harvard Medical School
H指数:61
被引数:2.2万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial

利扎布鲁替尼在既往治疗过的免疫性血小板减少症患者中的临床活性和安全性(LUNA3):一项III期试验开放标签期的结果

2026-09-170
PRE
Supportive strategies in thrombocytopenia: Platelet transfusion and beyond

血小板减少症的支持性策略:血小板输注及其它方法

2026-07-011
PRE
The hunt for a cure: modern medical approaches for immune thrombocytopenia

寻找治疗方法:免疫性血小板减少症的现代医学方法

2026-05-010
PRE
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study

Evans综合征在妊娠期及产后期:一项回顾性队列研究

2025-09-090
PRE
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia

评估rilzabrutinib在免疫性血小板减少症治疗中的应用

2025-08-110
OA
Safety and efficacy of daratumumab in immune thrombocytopenia

达雷木单抗在免疫性血小板减少症中的安全性与有效性

2025-08-070
OAAI
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study

利扎布鲁替尼(Rilzabrutinib)的疗效和安全性结果:一项在免疫性血小板减少症患者中的口服布鲁顿酪氨酸激酶抑制剂Ⅱ期B部分研究

2025-01-221
OA
Clinical Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with Advanced Therapies in the United States

美国接受先进疗法治疗的持续性或慢性原发性免疫性血小板减少症患者疾病负担研究

BLOOD
IF23.1
2024-11-050
PRE
Cognitive impairment among patients with chronic immune thrombocytopenia

慢性免疫性血小板减少症患者的认知功能障碍

2024-05-090
OAAI
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
2024-03-294
OAAI
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study (vol 101, pg 2169, 2022)
2024-03-230
OAAI
The latest insights into rare blood disorders: Diagnosis and treatment strategies
2024-03-090
OA
Avatrombopag for adults with early versus chronic immune thrombocytopenia
2023-12-085
OAAI
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)
2023-11-068
OAAI
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
LANCET
IF88.5
2023-11-0111
PRE
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
2023-11-0124
OA
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
2023-10-189
OAAI
New insights into the glycobiology of immune thrombocytopenia
2023-07-275
PRE
Donor-derived disorders of hemostasis and thrombosis in liver transplantation: Considerations for deceased donor liver selection
2023-07-250
PRE
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
2023-05-2912
OAAI